宫颈癌预防性疫苗接种：韩国妇科肿瘤学会指南
Preventive vaccination against cervical cancer: Korean Society of Gynecologic Oncology Guideline.
作者信息
Min Kyung-Jin, Kwon Sang-Hoon, Kim Sunghoon, Kim Hyun Jung, Seong Seok Ju, Song Yong Jung, Shin Jin Woo, Lee Keun-Ho, Lim Myong Cheol, Chung Hyun Hoon, Ju Woong, Hong Jin Hwa, Lee Jeong-Won, Kim Jae-Weon, Bae Duk-Soo, Lee Jae-Kwan
机构信息
Department of Obstetrics and Gynecology, Korea University Medical Center, Korea University College of Medicine, Seoul, Korea.
Department of Obstetrics and Gynecology, Keimyung University School of Medicine, Daegu, Korea.
出版信息
J Gynecol Oncol. 2016 May;27(3):e30. doi: 10.3802/jgo.2016.27.e30.
Abstract
After human papillomavirus (HPV) vaccine guidelines published by Korean Society of Gynecologic Oncology (KSGO) in 2011, new studies have been published, leading to additional data regarding efficacy, safety, number of vaccination rounds, and ideal age of vaccine administration. We searched and reviewed the literatures focused on the efficacy of 2-dose schedule vaccination, the efficacy of 3-dose schedule vaccination in middle-aged women, the ideal age of 3-dose schedule vaccination, the safety of HPV preventive vaccine, and the ability of cross-protection of each HPV preventive vaccine. The KSGO has revised the previous guideline based on the results of the above studies.
摘要
韩国妇科肿瘤学会（KSGO）于2011年发布人乳头瘤病毒（HPV）疫苗指南后，新的研究相继发表，产生了关于疫苗效力、安全性、接种针次及理想接种年龄的更多数据。我们检索并综述了聚焦于2剂次接种方案的效力、中年女性3剂次接种方案的效力、3剂次接种方案的理想接种年龄、HPV预防性疫苗的安全性以及各HPV预防性疫苗交叉保护能力的文献。KSGO已根据上述研究结果修订了先前的指南。
相似文献
1
Preventive vaccination against cervical cancer: Korean Society of Gynecologic Oncology Guideline.宫颈癌预防性疫苗接种：韩国妇科肿瘤学会指南
J Gynecol Oncol. 2016 May;27(3):e30. doi: 10.3802/jgo.2016.27.e30.
2
Clinical guideline for 9-valent HPV vaccine: Korean Society of Gynecologic Oncology Guideline.《九价人乳头瘤病毒疫苗临床应用指南：韩国妇科肿瘤学会指南》
J Gynecol Oncol. 2019 Mar;30(2):e31. doi: 10.3802/jgo.2019.30.e31. Epub 2019 Jan 9.
3
Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP).四价人乳头瘤病毒疫苗：免疫实践咨询委员会（ACIP）的建议
MMWR Recomm Rep. 2007 Mar 23;56(RR-2):1-24.
4
Use of the nonavalent HPV vaccine in individuals previously fully or partially vaccinated with bivalent or quadrivalent HPV vaccines.在先前已全程或部分接种二价或四价人乳头瘤病毒（HPV）疫苗的个体中使用九价HPV疫苗。
Vaccine. 2016 Feb 3;34(6):757-61. doi: 10.1016/j.vaccine.2015.12.063. Epub 2016 Jan 6.
5
HPV single-dose vaccination: Impact potential, evidence base and further evaluation.人乳头瘤病毒单剂量疫苗接种：潜在影响、证据基础及进一步评估
Vaccine. 2018 Aug 6;36(32 Pt A):4759-4760. doi: 10.1016/j.vaccine.2018.02.076. Epub 2018 May 10.
6
Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial.24至45岁女性四价人乳头瘤病毒（6、11、16、18型）重组疫苗的安全性、免疫原性及有效性：一项随机双盲试验
Lancet. 2009 Jun 6;373(9679):1949-57. doi: 10.1016/S0140-6736(09)60691-7. Epub 2009 Jun 1.
7
Updated clinical guideline for human papillomavirus vaccine: the Korean Society of Gynecologic Oncology guidelines.人乳头瘤病毒疫苗更新临床指南：韩国妇科肿瘤学会指南。
J Gynecol Oncol. 2021 Nov;32(6):e94. doi: 10.3802/jgo.2021.32.e94.
8
Spotlight on quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine(Gardasil®) in the prevention of premalignant genital lesions, genital cancer, and genital warts in women.重点介绍四价人乳头瘤病毒（6、11、16、18 型）重组疫苗（佳达修®）在预防女性的癌前生殖器病变、生殖器癌和生殖器疣方面的作用。
BioDrugs. 2011 Oct 1;25(5):339-43. doi: 10.2165/11205060-000000000-00000.
9
Human Pappilomavirus (HPV) induced cancers and prevention by immunization.人乳头瘤病毒（HPV）引发的癌症及免疫预防
Pak J Pharm Sci. 2012 Oct;25(4):763-72.
10
Cost-effectiveness of HPV vaccination in Belize.伯利兹人乳头瘤病毒疫苗接种的成本效益
Vaccine. 2015 May 7;33 Suppl 1:A174-81. doi: 10.1016/j.vaccine.2014.12.042.
引用本文的文献
1
Updated clinical guideline for human papillomavirus vaccine: the Korean Society of Gynecologic Oncology guidelines.人乳头瘤病毒疫苗更新临床指南：韩国妇科肿瘤学会指南。
J Gynecol Oncol. 2021 Nov;32(6):e94. doi: 10.3802/jgo.2021.32.e94.
2
Status of HPV vaccination among HPV-infected women aged 20-60 years with abnormal cervical cytology in South Korea: a multicenter, retrospective study.韩国 20-60 岁 HPV 感染伴宫颈细胞学异常女性 HPV 疫苗接种状况：一项多中心回顾性研究。
J Gynecol Oncol. 2020 Jan;31(1):e4. doi: 10.3802/jgo.2020.31.e4. Epub 2019 Jun 28.
3
Asian Society of Gynecologic Oncology International Workshop 2018.亚洲妇科肿瘤学会国际研讨会 2018 年。
J Gynecol Oncol. 2019 Mar;30(2):e39. doi: 10.3802/jgo.2019.30.e39. Epub 2019 Jan 14.
4
Clinical guideline for 9-valent HPV vaccine: Korean Society of Gynecologic Oncology Guideline.《九价人乳头瘤病毒疫苗临床应用指南：韩国妇科肿瘤学会指南》
J Gynecol Oncol. 2019 Mar;30(2):e31. doi: 10.3802/jgo.2019.30.e31. Epub 2019 Jan 9.
5
Updates on Cancer Epidemiology in Korea, 2018.2018年韩国癌症流行病学最新情况
Chonnam Med J. 2018 May;54(2):90-100. doi: 10.4068/cmj.2018.54.2.90. Epub 2018 May 25.
6
Multiple types of human papillomavirus infection and anal precancerous lesions in HIV-infected men in Taiwan: a cross-sectional study.台湾地区感染人类免疫缺陷病毒男性的多种人乳头瘤病毒感染与肛门癌前病变：一项横断面研究
BMJ Open. 2018 Jan 27;8(1):e019894. doi: 10.1136/bmjopen-2017-019894.
本文引用的文献
1
Evaluation of the immunogenicity of the quadrivalent HPV vaccine using 2 versus 3 doses at month 21: An epidemiological surveillance mechanism for alternate vaccination schemes.在第21个月时评估二剂次与三剂次四价人乳头瘤病毒疫苗的免疫原性：替代接种方案的流行病学监测机制
Hum Vaccin Immunother. 2016;12(1):30-8. doi: 10.1080/21645515.2015.1058458. Epub 2015 Jul 25.
2
Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine administered according to 2- and 3-dose schedules in girls aged 9-14 years: Results to month 12 from a randomized trial.9至14岁女孩中，按照2剂和3剂接种程序接种人乳头瘤病毒（HPV）-16/18 AS04佐剂疫苗和HPV-6/11/16/18疫苗的免疫原性和安全性比较：一项随机试验至第12个月的结果
Hum Vaccin Immunother. 2015;11(7):1689-702. doi: 10.1080/21645515.2015.1050570.
3
[Factors that influence sexual intercourse among middle school students: using data from the 8th (2012) Korea Youth Risk Behavior Web-based Survey].[影响中学生性行为的因素：基于第八次（2012年）韩国青少年风险行为网络调查的数据]
J Korean Acad Nurs. 2015 Feb;45(1):76-83. doi: 10.4040/jkan.2015.45.1.76.
4
Quadrivalent HPV vaccination and risk of multiple sclerosis and other demyelinating diseases of the central nervous system.四价人乳头瘤病毒疫苗接种与多发性硬化症及其他中枢神经系统脱髓鞘疾病的风险。
JAMA. 2015 Jan 6;313(1):54-61. doi: 10.1001/jama.2014.16946.
5
Comparison of long-term immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18-45 years: end-of-study analysis of a Phase III randomized trial.18至45岁健康女性中，人乳头瘤病毒（HPV）-16/18 AS04佐剂疫苗与HPV-6/11/16/18疫苗的长期免疫原性及安全性比较：一项III期随机试验的研究终期分析
Hum Vaccin Immunother. 2014;10(12):3435-45. doi: 10.4161/hv.36121.
6
Sustained efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine: final analysis of a long-term follow-up study up to 9.4 years post-vaccination.人乳头瘤病毒16/18型AS04佐剂疫苗的持续疗效、免疫原性及安全性：接种疫苗后长达9.4年的长期随访研究最终分析
Hum Vaccin Immunother. 2014;10(8):2147-62. doi: 10.4161/hv.29532.
7
Persistence of immune responses to the HPV-16/18 AS04-adjuvanted vaccine in women aged 15-55 years and first-time modelling of antibody responses in mature women: results from an open-label 6-year follow-up study.15-55 岁女性中 HPV-16/18 AS04 佐剂疫苗免疫应答的持久性和成熟女性中抗体应答的首次建模：一项开放标签 6 年随访研究的结果。
BJOG. 2015 Jan;122(1):107-18. doi: 10.1111/1471-0528.13070. Epub 2014 Sep 11.
8
Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 4-year interim follow-up of the phase 3, double-blind, randomised controlled VIVIANE study.HPV 16/18 AS04 佐剂疫苗在 25 岁以上女性中的功效、安全性和免疫原性：3 期、双盲、随机对照 VIVIANE 研究的 4 年中期随访。
Lancet. 2014 Dec 20;384(9961):2213-27. doi: 10.1016/S0140-6736(14)60920-X. Epub 2014 Sep 1.
9
Long-term study of a quadrivalent human papillomavirus vaccine.四价人乳头瘤病毒疫苗的长期研究。
Pediatrics. 2014 Sep;134(3):e657-65. doi: 10.1542/peds.2013-4144. Epub 2014 Aug 18.
10
Immune response to the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose or 3-dose schedule up to 4 years after vaccination: results from a randomized study.接种HPV-16/18 AS04佐剂疫苗2剂或3剂后长达4年的免疫反应：一项随机研究的结果
Hum Vaccin Immunother. 2014;10(5):1155-65. doi: 10.4161/hv.28022. Epub 2014 Feb 27.
Zotero 插件